首页> 外文期刊>British Journal of Cancer >Cell kinetics in leukaemia and solid tumours studied with in vivo bromodeoxyuridine and flow cytometry
【24h】

Cell kinetics in leukaemia and solid tumours studied with in vivo bromodeoxyuridine and flow cytometry

机译:体内溴脱氧尿苷和流式细胞仪研究白血病和实体瘤中的细胞动力学

获取原文
           

摘要

During a 15-month period, we used in vivo bromodeoxyuridine (BUDR) infusion to study cell kinetics in 112 consecutive patients with various types of malignant tumours: acute leukaemia (50 patients), gastric cancer (42) and brain gliomas (20). The in vivo BUDR method requires that a single tumour sample be taken 4-6 h after infusion and that bivariate flow cytometry (FCM) be employed to measure simultaneously the percentage of BUDR-labelled cells (which are identified with a green fluorescent anti-BUDR monoclonal antibody) and their mean DNA content (following propidium iodide staining). This technique rapidly furnishes the labelling index (LI) and the DNA synthesis time (TS), from which the tumour potential doubling time (Tpot) and production rate (fractional turnover rate, FTR) are calculated. The procedure took 6-9 h to complete and there was no immediate toxicity from BUDR administration. Successful LI and TS determinations were obtained in 89 (80%) and 80 (72%) of the 112 patients, respectively. Correlations were sought between kinetic parameters and a number of pathological and clinical ones. In 34 patients with acute non-lymphoblastic leukaemias who were uniformly treated for remission (CR) induction and maintenance, proliferative activity, as measured by Tpot and FTR, was greater in responsive than in non-responsive patients, and in those who experienced CR for over 8 months than in those who had a shorter CR. Proliferative activity was also greater in patients with advanced gastric cancers than in those with more limited disease. No correlations between kinetic and clinical and pathological parameters were found in gliomas. These data indicate the in vivo BUDR infusion coupled with FCM measurements can be performed in clinical settings to obtain kinetic data rapidly in quite large patient series. This will probably allow the inclusion of kinetic data in clinical trials aimed at evaluating the prognostic relevance of these data.
机译:在15个月的时间内,我们使用体内的溴脱氧尿苷(BUDR)输注研究了112例连续的各种类型的恶性肿瘤患者的细胞动力学:急性白血病(50例),胃癌(42例)和脑胶质瘤(20例)。体内BUDR方法要求在输注后4-6小时内采集单个肿瘤样本,并使用双变量流式细胞术(FCM)同时测量BUDR标记的细胞的百分比(已通过绿色荧光抗BUDR鉴定)单克隆抗体)及其平均DNA含量(碘化丙锭染色后)。该技术快速提供了标记指数(LI)和DNA合成时间(TS),从中可以计算出肿瘤的潜在倍增时间(Tpot)和生产率(分数周转率,FTR)。该过程需要6-9小时才能完成,BUDR给药不会立即产生毒性。在112例患者中,分别成功进行了LI和TS测定,分别为89(80%)和80(72%)。在动力学参数与许多病理和临床参数之间寻求相关性。在34例接受了缓解(CR)诱导和维持治疗的急性非淋巴细胞性白血病患者中,通过Tpot和FTR测得的增殖活性对非反应性患者的反应性大于非反应性患者,而经历CR的患者比那些CR较短的人超过8个月。与晚期胃癌相比,晚期胃癌患者的增殖活性也更高。在胶质瘤中没有发现动力学,临床和病理学参数之间的相关性。这些数据表明可以在临床环境中进行体内BUDR输注和FCM测量,以在相当大的患者系列中快速获得动力学数据。这可能将动力学数据纳入旨在评估这些数据的预后相关性的临床试验中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号